Axel Sjöblad, Managing Director of BioGaia AB, summarizes the second quarter of 2017 and answers questions regarding:

  • increase in sales and operating profit during this quarter compared to previous year
  • strong gross margin during the first half year
  • reasons behind the increase of operating expenses
  • strong growth in the Americas
  • start of subsidiary BioGaia Pharma
  • possible acquisition opportunities of other companies, strains or products

Listen to telephone conference from 18 August 2017 about Interim report 1 January-30 June 2017